



101 Barclay Street
22nd Floor
New York, NY 10286

February 26, 2016

Mr. Silvio Conte
The New York Stock Exchange

Depository Trust Company
mandatoryreorgannouncements@dtcc.com; adr@dtcc.com

Re: Mindray Medical International Limited (“MR”)
ADR Program Mandatory Exchange for Cash and ADR Termination
CUSIP #:602675100; ISIN #: US6026751007
ADR Ratio: 1 ADS: 1 Class A Ordinary share

At an extraordinary general meeting held on February 26, 2016, shareholders approved the previously announced agreement and plan of merger. As a result, Solid Union Limited (the “Merger Sub”) merged with and into MR with MR continuing as the surviving company as a wholly-owned subsidiary of Excelsior Union Limited (the “Parent”). Under the terms of the agreement and plan of merger, effective March 3, 2016 each MR ordinary share will automatically convert into the right to receive \$28.00 in cash without interest and less any applicable taxes, and each MR American Depositary Share (“ADS”) (CUSIP# 602675100) (each of which represents one ordinary shares) will automatically convert into the right to receive \$28.00 in cash without interest, less \$0.05 per ADS cancellation fee and less any applicable taxes.

BNY Mellon has announced that, effective March 8, 2016, registered holders of the ADSs of MR will be instructed to surrender their ADR certificates to BNY Mellon for cancellation on a mandatory basis in order to receive the following:

Payment of Merger Consideration:	
Gross Rate per ADS:	\$28.00
Depository Cancellation Fee:	-\$0.05
Net Rate per ADS:	\$27.95

Holders of MR ADSs in the Direct Registration System or in brokerage accounts will not need to surrender ADR certificates; they will receive payment directly by check from BNY Mellon or from their financial intermediaries.

Thank you in advance for your assistance. Feel free to contact me should you require further assistance.

Sincerely,

Paul Brophy
Vice President
T: +212-815-2301 / F: + 212-571-3050
paul.g.brophy@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt (“DR”) holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at <http://www.adrbnymellon.com/files/PB43451.pdf>. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.